<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01427504</url>
  </required_header>
  <id_info>
    <org_study_id>11-1046</org_study_id>
    <nct_id>NCT01427504</nct_id>
  </id_info>
  <brief_title>Potential for Drug-drug Interactions Between Boceprevir and Etravirine in HIV/Hepatitis C Virus Negative Volunteers</brief_title>
  <official_title>A Bioequivalence Study to Evaluate the Potential for Drug-drug Interactions Between Boceprevir 800mg Thrice Daily and the HIV Non-nucleoside Reverse Transcriptase Inhibitor Etravirine 200mg Twice Daily in HIV/(Hepatitis C Virus) (HCV) Negative Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Colorado, Denver</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Colorado, Denver</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators believe that boceprevir's drug concentrations will be reduced when
      administered in combination with etravirine. The investigators believe that etravirine's drug
      concentrations will be increased when administered in combination with boceprevir.
      Additionally, the investigators believe that boceprevir and etravirine are safe when
      administered alone or in combination.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To investigate the potential for drug interactions between boceprevir and etravirine,
      participants will receive each drug alone and the drugs in combination for 11-14 days. The
      pharmacokinetics of boceprevir and etravirine when given in combination vs. alone will be
      compared.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2011</start_date>
  <completion_date type="Actual">March 2012</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Boceprevir AUC Pharmacokinetics</measure>
    <time_frame>Pre-dose and, 1, 2, 3, 4, 5, 6, and 8 hours post dose on day 11-14</time_frame>
    <description>Determine boceprevir area-under-the concentration time curve (AUC) when administered alone.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Boceprevir Cmax Pharmacokinetics</measure>
    <time_frame>Pre-dose and, 1, 2, 3, 4, 5, 6, and 8 hours post dose on day 11-14</time_frame>
    <description>Determine the Cmax of boceprevir when administered alone.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Boceprevir C8 Pharmacokinetics</measure>
    <time_frame>Pre-dose and, 1, 2, 3, 4, 5, 6, and 8 hours post dose on day 11-14</time_frame>
    <description>Determine boceprevir 8 hour concentration when administered alone.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Etravirine AUC Pharmacokinetics</measure>
    <time_frame>Pre-dose and, 1, 2, 3, 4, 5, 6, 8, 10 and 12 hours post dose on day 11-14</time_frame>
    <description>Determine etravirine area under the concentration vs. time curve (AUC)when administered alone.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Etravirine Cmax Pharmacokinetics</measure>
    <time_frame>Pre-dose and, 1, 2, 3, 4, 5, 6, 8, 10 and 12 hours post dose on day 11-14</time_frame>
    <description>Determine etravirine Cmax when administered alone</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Etravirine Cmin Pharmacokinetics</measure>
    <time_frame>Pre-dose and, 1, 2, 3, 4, 5, 6, 8, 10 and 12 hours post dose on day 11-14</time_frame>
    <description>Determine etravirine Cmin when administered alone</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Boceprevir AUC Pharmacokinetics Coadministered With Etravirine</measure>
    <time_frame>Pre-dose and, 1, 2, 3, 4, 5, 6, and 8 hours post dose on day 11-14</time_frame>
    <description>Determine boceprevir AUC when coadministered with etravirine. [Ratio = boceprevir administered with etravirine/ boceprevir alone]</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Boceprevir Cmax Pharmacokinetics Coadministered With Etravirine</measure>
    <time_frame>Pre-dose and, 1, 2, 3, 4, 5, 6, and 8 hours post dose on day 11-14</time_frame>
    <description>Determine boceprevir Cmax when coadministered with etravirine. [Ratio = boceprevir administered with etravirine / boceprevir alone]</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Boceprevir C8 Pharmacokinetics Coadministered With Etravirine</measure>
    <time_frame>Pre-dose, 1, 2, 3, 4, 5, 6, and 8 hours post dose on day 11-14</time_frame>
    <description>Determine boceprevir 8 hour concentration when coadministered with etravirine. [Ratio = boceprevir administered with etravirine / boceprevir administered alone]</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Etravirine AUC Pharmacokinetics Coadministered With Boceprevir</measure>
    <time_frame>Pre-dose, 1, 2, 3, 4, 5, 6, 8, 10, and 12 hours Post-dose on day 11-14</time_frame>
    <description>Determine etravirine AUC when coadministered with boceprevir. [Ratio = Etravirine administered with bocepreivr / etravirine administered alone]</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Etravirine Cmax Pharmacokinetics Coadministered With Boceprevir</measure>
    <time_frame>Pre-dose, 1, 2, 3, 4, 5, 6, 8, 10, and 12 hours post-dose on day 11-14</time_frame>
    <description>Determine etravirine Cmax when coadministered with boceprevir. [Ratio = etravirine administered with boceprevir / etravirine administered alone]</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Etravirine Cmin Pharmacokinetics Coadministered With Boceprevir</measure>
    <time_frame>Pre-dose, 1, 2, 3, 4, 5, 6, 8, 10, and 12 hours post-dose on day 11-14</time_frame>
    <description>Determine etravirine Cmin when coadministered with boceprevir. [Ratio = etravirine administered with boceprevir / etravirine administered alone]</description>
  </primary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Hepatitis C</condition>
  <condition>HIV</condition>
  <arm_group>
    <arm_group_label>Sequence 1a</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sequence 1,2,3: boceprevir only, then etravirine only, then both boceprevir and etravirine.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 1b</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sequence 1,3,2: boceprevir only, then both boceprevir and etravirine, then etravirine only.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 2a</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sequence 2,1,3: etravirine only, then boceprevir only, then both boceprevir and etravirine.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 2b</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sequence 2,3,1: etravirine only, then both boceprevir and etravirine, then boceprevir only.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 3a</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sequence 3,1,2: both boceprevir and etravirine, then boceprevir only, then etravirine only.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 3b</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sequence 3,2,1: Both boceprevir and etravirine, then etravirine only, then boceprevir only.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>boceprevir; etravirine</intervention_name>
    <description>boceprevir tablets 800 mg, every 8 hours x 11-14 days. etravirine tablets 200 mg, every 12 hours x 11-14 days.</description>
    <arm_group_label>Sequence 1a</arm_group_label>
    <arm_group_label>Sequence 1b</arm_group_label>
    <arm_group_label>Sequence 2a</arm_group_label>
    <arm_group_label>Sequence 2b</arm_group_label>
    <arm_group_label>Sequence 3a</arm_group_label>
    <arm_group_label>Sequence 3b</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and women ages 18-60 years

          -  Absence of HIV-1 and HCV antibodies at screening

          -  Ability and willingness to give written informed consent before the first
             trial-related activity

        Exclusion Criteria:

          -  Pregnancy

          -  Breastfeeding

          -  Active alcohol or drug abuse that, in the opinion of the investigators, would
             interfere with adherence to study requirements.

          -  Participation in any investigation drug study within 30 days prior to study.

          -  Currently active or chronic gastrointestinal, cardiovascular, neurologic, psychiatric,
             metabolic, renal, hepatic, respiratory, inflammatory, or infectious disease or
             malignancy requiring pharmacologic treatment, and/or if in the opinion of the
             investigator, would affect study participation, safety, or integrity of results.

          -  Use of concomitant medication, including investigational, prescription, and
             over-the-counter products and dietary supplements with the following
             exceptions:aspirin, acetaminophen, once daily multivitamins, mineral supplements and
             hormonal oral contraceptives (other than those that contain drospirenone). Concomitant
             medications other than those listed above must have been discontinued at least 14 days
             before study entry.

          -  Currently active dermatitis or urticaria or diagnosis of eczema or psoriasis.

          -  History of significant drug allergy (i.e., anaphylaxis and/or angioedema)

          -  Subjects with the following laboratory abnormalities at screening as defined by the
             2004 Division of AIDS Table for grading the Severity of Adult and Pediatric Adverse
             Events and in accordance with the normal ranges of the trial clinical laboratory:
             serum creatinine grade 1 or greater (&gt;1.1 x upper limit of laboratory normal range
             (ULN); hemoglobin grade 1 or greater (≤ 10.9 g/dL); platelet count grade 1 or greater
             (≤ 124.999 x 109/L); absolute neutrophil count grade 1 or greater (≤ 1.3 x 109/L);
             aspartate aminotransferase (AST) or alanine aminotransferase (ALT) grade 1 or greater
             (≥ 1.25 x ULN); total bilirubin grade 1 or greater (≥ 1.1 x ULN), any other laboratory
             abnormality of grade 2 or above
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jennifer Kiser, PharmD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Univesity of Colorado Denver</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Colorado Anschutz Medical Campus</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 24, 2011</study_first_submitted>
  <study_first_submitted_qc>August 31, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 1, 2011</study_first_posted>
  <results_first_submitted>November 16, 2012</results_first_submitted>
  <results_first_submitted_qc>June 4, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 9, 2013</results_first_posted>
  <last_update_submitted>June 4, 2013</last_update_submitted>
  <last_update_submitted_qc>June 4, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 9, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HCV</keyword>
  <keyword>HIV</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Reverse Transcriptase Inhibitors</mesh_term>
    <mesh_term>Etravirine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment occured at the University of Colorado Hospital beginning September 1, 2011 and ended on October 4, 2011.</recruitment_details>
      <pre_assignment_details>There were 8 subjects that were excluded from trial before assignment to groups; 5 due to personal reasons, 2 due to elevated bilirubin, and 1 due to elevated serum creatinine.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Sequence 1a</title>
          <description>Sequence 1,2,3: boceprevir 800 mg three times daily alone, then etravirine 200 mg twice daily only, then both boceprevir 800 mg three times daily and etravirine 200 mg twice daily were each given for 11-14 days. Each intervention was followed by a 14 day washout period before the next sequence was started.</description>
        </group>
        <group group_id="P2">
          <title>Sequence 1b</title>
          <description>Sequence 1,3,2: boceprevir 800 mg three times daily alone, then etravirine 200 mg twice daily only, then both boceprevir 800 mg three times daily and etravirine 200 mg twice daily were each given for 11-14 days. Each intervention was followed by a 14 day washout period before the next sequence was started.</description>
        </group>
        <group group_id="P3">
          <title>Sequence 2a</title>
          <description>Sequence 2,1,3: boceprevir 800 mg three times daily alone, then etravirine 200 mg twice daily only, then both boceprevir 800 mg three times daily and etravirine 200 mg twice daily were each given for 11-14 days. Each intervention was followed by a 14 day washout period before the next sequence was started.</description>
        </group>
        <group group_id="P4">
          <title>Sequence 2b</title>
          <description>Sequence 2,3,1: boceprevir 800 mg three times daily alone, then etravirine 200 mg twice daily only, then both boceprevir 800 mg three times daily and etravirine 200 mg twice daily were each given for 11-14 days. Each intervention was followed by a 14 day washout period before the next sequence was started.</description>
        </group>
        <group group_id="P5">
          <title>Sequence 3a</title>
          <description>Sequence 3,1,2: boceprevir 800 mg three times daily alone, then etravirine 200 mg twice daily only, then both boceprevir 800 mg three times daily and etravirine 200 mg twice daily were each given for 11-14 days. Each intervention was followed by a 14 day washout period before the next sequence was started.</description>
        </group>
        <group group_id="P6">
          <title>Sequence 3b</title>
          <description>Sequence 3,2,1: boceprevir 800 mg three times daily alone, then etravirine 200 mg twice daily only, then both boceprevir 800 mg three times daily and etravirine 200 mg twice daily were each given for 11-14 days. Each intervention was followed by a 14 day washout period before the next sequence was started.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Boceprevir</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Etravirine</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Combination</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Sequence 1a</title>
          <description>Sequence 1,2,3: boceprevir only, then etravirine only, then both boceprevir and etravirine.</description>
        </group>
        <group group_id="B2">
          <title>Sequence 1b</title>
          <description>Sequence 1,3,2: boceprevir only, then both boceprevir and etravirine, then etravirine only.</description>
        </group>
        <group group_id="B3">
          <title>Sequence 2a</title>
          <description>Sequence 2,1,3: etravirine only, then boceprevir only, then both boceprevir and etravirine.</description>
        </group>
        <group group_id="B4">
          <title>Sequence 2b</title>
          <description>Sequence 2,3,1: etravirine only, then both boceprevir and etravirine, then boceprevir only.</description>
        </group>
        <group group_id="B5">
          <title>Sequence 3a</title>
          <description>Sequence 3,1,2: both boceprevir and etravirine, then boceprevir only, then etravirine only.</description>
        </group>
        <group group_id="B6">
          <title>Sequence 3b</title>
          <description>Sequence 3,2,1: Both boceprevir and etravirine, then etravirine only, then boceprevir only.</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="4"/>
            <count group_id="B2" value="3"/>
            <count group_id="B3" value="4"/>
            <count group_id="B4" value="6"/>
            <count group_id="B5" value="3"/>
            <count group_id="B6" value="6"/>
            <count group_id="B7" value="26"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42.7" spread="13.4"/>
                    <measurement group_id="B2" value="35.6" spread="8.0"/>
                    <measurement group_id="B3" value="33.3" spread="9.8"/>
                    <measurement group_id="B4" value="25.9" spread="3.8"/>
                    <measurement group_id="B5" value="42.7" spread="16.8"/>
                    <measurement group_id="B6" value="32.4" spread="9.3"/>
                    <measurement group_id="B7" value="34.2" spread="10.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Boceprevir AUC Pharmacokinetics</title>
        <description>Determine boceprevir area-under-the concentration time curve (AUC) when administered alone.</description>
        <time_frame>Pre-dose and, 1, 2, 3, 4, 5, 6, and 8 hours post dose on day 11-14</time_frame>
        <population>The number of participants was based on the number of subjects that completed all three sequences of medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Boceprevir AUC</title>
            <description>Geometric mean of boceprevir AUC administered alone.</description>
          </group>
        </group_list>
        <measure>
          <title>Boceprevir AUC Pharmacokinetics</title>
          <description>Determine boceprevir area-under-the concentration time curve (AUC) when administered alone.</description>
          <population>The number of participants was based on the number of subjects that completed all three sequences of medication.</population>
          <units>ng*hr/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4601" spread="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Boceprevir Cmax Pharmacokinetics</title>
        <description>Determine the Cmax of boceprevir when administered alone.</description>
        <time_frame>Pre-dose and, 1, 2, 3, 4, 5, 6, and 8 hours post dose on day 11-14</time_frame>
        <population>The number of participants is based on the number of subjects that completed all three sequences of medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Boceprevir Cmax</title>
            <description>Geometric mean of boceprevir Cmax when administered alone.</description>
          </group>
        </group_list>
        <measure>
          <title>Boceprevir Cmax Pharmacokinetics</title>
          <description>Determine the Cmax of boceprevir when administered alone.</description>
          <population>The number of participants is based on the number of subjects that completed all three sequences of medication.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1423" spread="43" lower_limit="0.66" upper_limit="0.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Boceprevir C8 Pharmacokinetics</title>
        <description>Determine boceprevir 8 hour concentration when administered alone.</description>
        <time_frame>Pre-dose and, 1, 2, 3, 4, 5, 6, and 8 hours post dose on day 11-14</time_frame>
        <population>The number of participants is based on the number of subjects that completed all three sequences of medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Boceprevir C8</title>
            <description>Geometric mean of boceprevir Cmax when administered alone.</description>
          </group>
        </group_list>
        <measure>
          <title>Boceprevir C8 Pharmacokinetics</title>
          <description>Determine boceprevir 8 hour concentration when administered alone.</description>
          <population>The number of participants is based on the number of subjects that completed all three sequences of medication.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="106" spread="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Etravirine AUC Pharmacokinetics</title>
        <description>Determine etravirine area under the concentration vs. time curve (AUC)when administered alone.</description>
        <time_frame>Pre-dose and, 1, 2, 3, 4, 5, 6, 8, 10 and 12 hours post dose on day 11-14</time_frame>
        <population>The number of participants is based on the number of subjects that completed all three sequences of medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Etravirine AUC</title>
            <description>Geometric mean of etravirine AUC when administered alone.</description>
          </group>
        </group_list>
        <measure>
          <title>Etravirine AUC Pharmacokinetics</title>
          <description>Determine etravirine area under the concentration vs. time curve (AUC)when administered alone.</description>
          <population>The number of participants is based on the number of subjects that completed all three sequences of medication.</population>
          <units>ng*hr/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7698" spread="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Etravirine Cmax Pharmacokinetics</title>
        <description>Determine etravirine Cmax when administered alone</description>
        <time_frame>Pre-dose and, 1, 2, 3, 4, 5, 6, 8, 10 and 12 hours post dose on day 11-14</time_frame>
        <population>The number of participants is based on the number of subjects that completed all three sequences of medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Etravirine Cmax</title>
            <description>Geometric mean of etravirine Cmax when administered alone.</description>
          </group>
        </group_list>
        <measure>
          <title>Etravirine Cmax Pharmacokinetics</title>
          <description>Determine etravirine Cmax when administered alone</description>
          <population>The number of participants is based on the number of subjects that completed all three sequences of medication.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="900" spread="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Etravirine Cmin Pharmacokinetics</title>
        <description>Determine etravirine Cmin when administered alone</description>
        <time_frame>Pre-dose and, 1, 2, 3, 4, 5, 6, 8, 10 and 12 hours post dose on day 11-14</time_frame>
        <population>The number of participants is based on the number of subjects that completed all three sequences of medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Etravirine Cmin</title>
            <description>Geometric mean of etravirine Cmin when administered alone.</description>
          </group>
        </group_list>
        <measure>
          <title>Etravirine Cmin Pharmacokinetics</title>
          <description>Determine etravirine Cmin when administered alone</description>
          <population>The number of participants is based on the number of subjects that completed all three sequences of medication.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="439" spread="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Boceprevir AUC Pharmacokinetics Coadministered With Etravirine</title>
        <description>Determine boceprevir AUC when coadministered with etravirine. [Ratio = boceprevir administered with etravirine/ boceprevir alone]</description>
        <time_frame>Pre-dose and, 1, 2, 3, 4, 5, 6, and 8 hours post dose on day 11-14</time_frame>
        <population>The number of participants is based on the number of subjects that completed all three sequences of medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Boceprevir AUC Coadministered With Etravirine</title>
            <description>Geometric mean ratio of boceprevir AUC when coadministered with etravirine</description>
          </group>
        </group_list>
        <measure>
          <title>Boceprevir AUC Pharmacokinetics Coadministered With Etravirine</title>
          <description>Determine boceprevir AUC when coadministered with etravirine. [Ratio = boceprevir administered with etravirine/ boceprevir alone]</description>
          <population>The number of participants is based on the number of subjects that completed all three sequences of medication.</population>
          <units>Ratio</units>
          <param>Geometric Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.10" lower_limit="0.94" upper_limit="1.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Boceprevir Cmax Pharmacokinetics Coadministered With Etravirine</title>
        <description>Determine boceprevir Cmax when coadministered with etravirine. [Ratio = boceprevir administered with etravirine / boceprevir alone]</description>
        <time_frame>Pre-dose and, 1, 2, 3, 4, 5, 6, and 8 hours post dose on day 11-14</time_frame>
        <population>The number of participants is based on the number of subjects that completed all three sequences of medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Boceprevir Cmax Coadministered With Etravirine</title>
            <description>Geometric mean ratio of boceprevir Cmax when coadministered with etravirine</description>
          </group>
        </group_list>
        <measure>
          <title>Boceprevir Cmax Pharmacokinetics Coadministered With Etravirine</title>
          <description>Determine boceprevir Cmax when coadministered with etravirine. [Ratio = boceprevir administered with etravirine / boceprevir alone]</description>
          <population>The number of participants is based on the number of subjects that completed all three sequences of medication.</population>
          <units>Ratio</units>
          <param>Geometric Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.10" lower_limit="0.94" upper_limit="1.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Boceprevir C8 Pharmacokinetics Coadministered With Etravirine</title>
        <description>Determine boceprevir 8 hour concentration when coadministered with etravirine. [Ratio = boceprevir administered with etravirine / boceprevir administered alone]</description>
        <time_frame>Pre-dose, 1, 2, 3, 4, 5, 6, and 8 hours post dose on day 11-14</time_frame>
        <population>The number of participants is based on the number of subjects that completed all three sequences of medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Boceprevir C8 Coadministered With Etravirine</title>
            <description>Geometric mean ratio of boceprevir C8 when coadministered with etravirine</description>
          </group>
        </group_list>
        <measure>
          <title>Boceprevir C8 Pharmacokinetics Coadministered With Etravirine</title>
          <description>Determine boceprevir 8 hour concentration when coadministered with etravirine. [Ratio = boceprevir administered with etravirine / boceprevir administered alone]</description>
          <population>The number of participants is based on the number of subjects that completed all three sequences of medication.</population>
          <units>Ratio</units>
          <param>Geometric Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.88" lower_limit="0.66" upper_limit="1.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Etravirine AUC Pharmacokinetics Coadministered With Boceprevir</title>
        <description>Determine etravirine AUC when coadministered with boceprevir. [Ratio = Etravirine administered with bocepreivr / etravirine administered alone]</description>
        <time_frame>Pre-dose, 1, 2, 3, 4, 5, 6, 8, 10, and 12 hours Post-dose on day 11-14</time_frame>
        <population>The number of participants is based on the number of subjects that completed all three sequences of medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Etravirine AUC Coadministered With Boceprevir</title>
            <description>Geometric mean ratio of etravirine AUC when coadministered with boceprevir</description>
          </group>
        </group_list>
        <measure>
          <title>Etravirine AUC Pharmacokinetics Coadministered With Boceprevir</title>
          <description>Determine etravirine AUC when coadministered with boceprevir. [Ratio = Etravirine administered with bocepreivr / etravirine administered alone]</description>
          <population>The number of participants is based on the number of subjects that completed all three sequences of medication.</population>
          <units>Ratio</units>
          <param>Geometric Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.77" lower_limit="0.66" upper_limit="0.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Etravirine Cmax Pharmacokinetics Coadministered With Boceprevir</title>
        <description>Determine etravirine Cmax when coadministered with boceprevir. [Ratio = etravirine administered with boceprevir / etravirine administered alone]</description>
        <time_frame>Pre-dose, 1, 2, 3, 4, 5, 6, 8, 10, and 12 hours post-dose on day 11-14</time_frame>
        <population>The number of participants is based on the number of subjects that completed all three sequences of medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Etravirine Cmax</title>
            <description>Geometric mean ratio of etravirine Cmax when coadministered with boceprevir</description>
          </group>
        </group_list>
        <measure>
          <title>Etravirine Cmax Pharmacokinetics Coadministered With Boceprevir</title>
          <description>Determine etravirine Cmax when coadministered with boceprevir. [Ratio = etravirine administered with boceprevir / etravirine administered alone]</description>
          <population>The number of participants is based on the number of subjects that completed all three sequences of medication.</population>
          <units>Ratio</units>
          <param>Geometric Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.76" lower_limit="0.68" upper_limit="0.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Etravirine Cmin Pharmacokinetics Coadministered With Boceprevir</title>
        <description>Determine etravirine Cmin when coadministered with boceprevir. [Ratio = etravirine administered with boceprevir / etravirine administered alone]</description>
        <time_frame>Pre-dose, 1, 2, 3, 4, 5, 6, 8, 10, and 12 hours post-dose on day 11-14</time_frame>
        <population>The number of participants is based on the number of subjects that completed all three sequences of medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Etravirine Cmin Coadministered With Boceprevir</title>
            <description>Geometric mean ratio of etravirine Cmin when coadministered with boceprevir</description>
          </group>
        </group_list>
        <measure>
          <title>Etravirine Cmin Pharmacokinetics Coadministered With Boceprevir</title>
          <description>Determine etravirine Cmin when coadministered with boceprevir. [Ratio = etravirine administered with boceprevir / etravirine administered alone]</description>
          <population>The number of participants is based on the number of subjects that completed all three sequences of medication.</population>
          <units>Ratio</units>
          <param>Geometric Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.71" lower_limit="0.54" upper_limit="0.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>4 months</time_frame>
      <desc>Adverse events were verbally assessed by study investigators. Laboratory tests were performed at baseline and at all three intensive pharmacokinetic study visits. Clinical and laboratory adverse events were graded using the 2004 Division of AIDS table for grading the severity of adult and pediatric adverse experiences.</desc>
      <group_list>
        <group group_id="E1">
          <title>Boceprevir Alone</title>
          <description>Subjects took boceprevir alone, 800 mg thrice daily, for 10-14 days.</description>
        </group>
        <group group_id="E2">
          <title>Etravirine Alone</title>
          <description>Subjects took etravirine alone, 200 mg twice daily, for 10-14 days</description>
        </group>
        <group group_id="E3">
          <title>Boceprevir Coadministered With Etravirine</title>
          <description>Boceprevir, 800 mg thrice daily, coadministered with etravirine, 200 mg twice daily for 10-14 days.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>Serious, Mild/Mod</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Presumed Viral Illness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Increased energy, anxiety, nervousness, insomnia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title vocab="Grade 2">Rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>Serious, Mild/Mod</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Altered Taste</sub_title>
                <counts group_id="E1" events="18" subjects_affected="18" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" events="16" subjects_affected="16" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="21"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="22"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="21"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="22"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="21"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Healthy volunteer study does not take into account other medications being prescribed to treat the co-infected population.
An interaction at the level of enzyme induction is difficult to rule out since we sampled etravirine over 12 hours.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Jennifer Kiser</name_or_title>
      <organization>University of Colorado</organization>
      <phone>303-724-6131</phone>
      <email>jennifer.kiser@ucdenver.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

